Johnson and Johnson Halts Clinical Trial for Atopic Dermatitis Drug
Johnson & Johnson halted a mid-stage trial for an atopic dermatitis drug after it failed efficacy goals. The decision affects their dermatology segment.
Insights:
Johnson & Johnson has announced the discontinuation of a mid-stage clinical trial for an experimental atopic dermatitis drug. This decision comes after the drug failed to meet the necessary efficacy goals during an interim analysis. The announcement was made on December 26, marking a significant setback for the company's dermatology segment.
